+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The mechanism of transport of the multitargeted antifolate (MTA) and its cross-resistance pattern in cells with markedly impaired transport of methotrexate



The mechanism of transport of the multitargeted antifolate (MTA) and its cross-resistance pattern in cells with markedly impaired transport of methotrexate



Clinical Cancer Research 6(9): 3687-3695



MTA (LY231514) is an antifolate that targets multiple folate-dependent enzymes. In this report, MTA transport was characterized in wild-type L1210 cells and variants with impaired membrane transport or polyglutamation. MTA influx via the reduced folate carrier was somewhat faster (approximately 30%) than that for methotrexate (MTX). Unlike MTX, MTA was rapidly polyglutamated in L1210 cells; hence, a folylpoly-gamma-glutamate synthetase-deficient L1210 variant was used to assess net transport and efflux properties. The MTA transmembrane gradient for exchangeable drug was 2.5 times greater than the MTX gradient, attributable primarily to an efflux rate constant 40% that of MTX. No MTA was bound to dihydrofolate reductase. When grown with folic acid, MTX-resistant L1210 variants with mutations in the reduced folate carrier demonstrated cross-resistance to MTA, markedly reduced MTA accumulation, and only a slightly decreased intracellular folate cofactor pool as compared to L1210 cells. However, when 5-formyltetrahydrofolate was the growth substrate, these MTX-resistant cells were less resistant or negligibly resistant to MTA, accumulated more MTA, and had a lower folate pool as compared to L1210 cells. MTA activity and the intracellular folate pool in L1210 cells were inversely related. These data indicate that MTA polyglutamation in L1210 cells is favored by both the generation of high intracellular drug levels and high MTA affinity for FPGS relative to MTX. Cells resistant to MTX because of impaired transport may retain appreciable sensitivity to MTA because of a concurrent reduction in tetrahydrofolate cofactor transport resulting in cellular folate depletion, which diminishes endogenous folate suppression of MTA polyglutamation.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 047679796

Download citation: RISBibTeXText

PMID: 10999762


Related references

Determinants of the disparate antitumor effects of (6R)5,10-dideaza-5,6,7,8- tetrahydrofolate and methotrexate toward methotrexate resistant CCRF-CEM cells, characterized by severely impaired antifolate membrane transport. Advances in Experimental Medicine and Biology 338: 783-786, 1993

Enhanced antitumor activity of 5,10-dideazatetrahydrofolate toward methotrexate resistant CCRF-CEM cells, with severely impaired antifolate transport. Proceedings of the American Association for Cancer Research Annual Meeting 34(0): 276, 1993

Minimal change in transport and growth requirement for folic acid fa in an l1210 leukemia cell line with markedly impaired transport of methotrexate mtx. Proceedings of the American Association for Cancer Research Annual Meeting 29: 283, 1988

Determinants of the disparate antitumor activities of (6R)-5,10-dideaza-5,6,7,8-tetrahydrofolate and methotrexate toward human lymphoblastic leukemia cells, characterized by severely impaired antifolate membrane transport. Biochemical Pharmacology 46(12): 2185-2195, 1993

Resistance to the antifolate PT523 is conferred by markedly defective reduced folate carrier transport. Proceedings of the American Association for Cancer Research Annual Meeting (41): 7, March, 2000

Molecular mechanism of antifolate transport-deficiency in a methotrexate-resistant MOLT-3 human leukemia cell line. Blood 89(7): 2494-2499, 1997

Antifolate resistance associated with loss of MRP1 expression and function in Chinese hamster ovary cells with markedly impaired export of folate and cholate. Molecular Pharmacology 64(2): 220-227, 2003

MTA transport is more concentrative than that of methotrexate in L1210 leukemia cells with relative preservation of antitumor activity in cell lines resistant to MTX due to impaired transport. Proceedings of the American Association for Cancer Research Annual Meeting (41): 4, March, 2000

Antifolate resistance in a HeLa cell line associated with impaired transport independent of the reduced folate carrier. Clinical Cancer Research 10(24): 8735-8742, 2004

Elevated dihydrofolate reductase and impaired methotrexate transport as elements in methotrexate resistance in childhood acute lymphoblastic leukemia. Blood 85(2): 500-509, 1995

Biological activity of the multitargeted antifolate, MTA , in human cell lines with different resistance mechanisms to antifolate drugs. Seminars in Oncology 26(2 SUPPL 6): 68-73, April, 1999

Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs. Seminars in Oncology 26(2 Suppl 6): 68-73, 1999

Transport of a fluorescent antifolate by methotrexate-sensitive and methotrexate-resistant human leukemic lymphoblasts. Biochemical Pharmacology 35(2): 356-360, 1986

Detective transport of amethopterin (methotrexate) as a mechanism of resistance to the antimetabolite in L5178Y leukemic cells. Biochemical Pharmacology 11: 1233-1234, 1962